MCMauricio Magalhaes Costa

Mauricio Magalhaes Costa

*This is an algorithmically generated author record based on publicly available information.

Mauricio Magalhaes Costa has a total of 258 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cancer in Pregnancy: Therapeutic Decisions at the Intersection of Two Lives

    by Antônio Braga, Jorge de Rezende-Filho, Maurício Magalhães, Sue Yazaki Sun, Andreia Cristina de Melo, Gustavo Yano Callado, Fernanda da Costa Negraes, Maria Vitória Moura Fajardo, Susana Cristina Aidé Viviani Fialho, Edward Araujo Júnior, et al.

    Background: Cancer during pregnancy is a rare but increasingly encountered condition due to delayed childbearing and improved survival of women with cancer. The coexistence of malignancy and pregnancy poses complex diagnostic and therapeutic challenges, requiring careful balance between maternal prognosis and fetal safety. Objective: This review aims to summarize current evidence on the diagnosis and multidisciplinary management of cancer during pregnancy, focusing on the safe use of oncologic therapies, obstetric decision-making, and maternal and fetal outcomes. Methods: A narrative review was conducted based on literature identified in PubMed/MEDLINE, Scopus, and Web of Science from January 2000 to September 2025. Search terms included pregnancy-associated cancer, oncologic treatment during pregnancy, obstetric management, and fetal outcomes. Relevant clinical guidelines, registry data, and reference lists were also reviewed. Results: Breast cancer, cervical cancer, melanoma, hematologic malignancies, and gestational trophoblastic neoplasia represent the most frequently reported cancers during pregnancy. Evidence indicates that selected cancer treatments can be administered safely without compromising maternal prognosis. Chemotherapy after the first trimester is generally associated with acceptable fetal outcomes. Physiological changes in pregnancy may delay diagnosis and influence drug pharmacokinetics. Radiotherapy, targeted therapies, and immunotherapies remain limited because of potential fetal toxicity. Avoiding iatrogenic prematurity is a central principle of obstetric management. Conclusions: Cancer during pregnancy should no longer be considered an absolute therapeutic dilemma. With individualized multidisciplinary care, effective maternal treatment and favorable fetal outcomes are increasingly achievable.


  • Open Access

    What Changes are Mandatory in Breast Surgery Training? An International Survey and Recommendations of the French Academy of Surgery and the Senologic International Society

    by Tolga Ozmen, Caroline Bouche, Megane Buttignol, Bolivar Arboleda-Osorio, Mauricio Magalhaes Costa, Henry Coudane, Darius Dian, Xishan Hao, Shigeru Imoto, Olivier Jardé, et al.

    What Changes are Mandatory in Breast Surgery Training? An International Survey and Recommendations of the French Academy of Surgery and the Senologic International Society - European Journal of Breast Health


  • Open Access

    Use of 125 iodine seeds for intra-operative localization of nonpalpable breast lesions (ROLLIS): analysis of the implant of 1757 seeds in 1477 patients

    by Antônio Campbell Penna, Carlos Antônio da Silva Franca, Maria Veronica Fonseca Torres de Oliveira, Lea Mirian Barbosa da Fonseca, Paula de Azevedo Brant Saldanha, Jacir Luiz Balen, Augusto Cesar Peixoto Rocha, Fernanda Philadelpho Arantes Pereira, Valeska Caldoncelli Andrade, Rafael Henrique Szymanski Machado, et al.

    Objective: To analyze the feasibility, efficacy and results of the use of 125Iodine seeds for intra-operative localization of nonpalpable breast lesions. Method: Retrospective review of 1477 patients referred by various breast specialist surgeons, with radiologically detected but clinically nonpalpable microcalcifications, asymmetric density or nodules, submitted to pre-operatory 125Iodine seed implant, between July 2012 and September 2023. A total of 1757 seeds were implanted in ordinary radiologic departments, supported by ultrasonography or mammography exams, chosen according to the morphologic aspect of the lesion. Radioguided surgical procedure took place on the same day or few days after the implant of the seeds, with the help of a radiation detector called Gamaprobe, which directs the surgeons towards the radioactive seeds and to the lesion to be resected. Results: All implants were performed as outpatient procedures, with patients immediately returning to their daily activities. No complications such as pain, bleeding, infection, and hematoma were recorded. Pathologists had no difficulty in preparing the surgical specimens for histopathologic analysis. Surgical safety margins were considered adequate in all pathologic reports, with no need for re-operations. The healing process was not jeopardized by radiation, and the surgeons were pleased with the improvement in intraoperative lesion localizations and the shortening on operatory time. Cosmetic results were well accepted by the patients. Conclusion: The 125Iodine seed implant is an effective alternative method for intraoperative localization of radiologically detectable and clinically nonpalpable breast lesions.

  • Current Challenges and Perspectives in Breast Cancer in Elderly Women: The Senologic International Society (SIS) Survey

    by Louise Scheer, Massimo Lodi, Tolga Özmen, Khalid Alghamdi, Stanley Anyanwu, Joshi Birendra, Mohsen Boubnider, Mauricio Costa, Darius Dian, Elisabeth Elder, et al.

    Mammographic screening and management of breast cancer (BC) in elderly women are controversial and continue to be an important health problem. To investigate, through members of the Senologic International Society (SIS), the current global practices in BC in elderly women, highlighting topics of debate and suggesting perspectives. The questionnaire was sent to the SIS network and included 55 questions on definitions of an elderly woman, BC epidemiology, screening, clinical and pathological characteristics, therapeutic management in elderly women, onco-geriatric assessment and perspectives. Twenty-eight respondents from 21 countries and six continents, representing a population of 2.86 billion, completed and submitted the survey. Most respondents considered women 70 years and older to be elderly. In most countries, BC was often diagnosed at an advanced stage compared to younger women, and age-related mortality was high. For this reason, participants recommended that personalized screening be continued in elderly women with a long life expectancy. In addition, this survey highlighted that geriatric frailty assessment tools and comprehensive geriatric evaluations needed to be used more and should be developed to avoid undertreatment. Similarly, multidisciplinary meetings dedicated to elderly women with BC should be encouraged to avoid under- and over-treatment and to increase their participation in clinical trials. Due to increased life expectancy, BC in elderly women will become a more important field in public health. Therefore, screening, personalized treatment, and comprehensive geriatric assessment should be the cornerstones of future practice to avoid the current excess of age-related mortality. This survey described, through members of the SIS, a global picture of current international practices in BC in elderly women.


  • The Senologic International Society Survey on Ductal Carcinoma In Situ: Present and Future

    by Carole Mathelin, Massimo Lodi, Khalid Alghamdi, Bolivar Arboleda-Osorio, Eli Avisar, Stanley Anyanwu, Mohcen Boubnider, Mauricio Maghales Costa, Elisabeth Elder, Tony Elonge, et al.

    Objective: Therapeutic management of ductal carcinoma in situ (DCIS) is heterogeneous among countries worldwide, and some treatment indications are still controversial. To investigate DCIS management in different countries; identify both consensual practices and controversial topics; and survey opinions about the future management of DCIS. Materials and Methods: The Senologic International Society network members participated to an online survey using a questionnaire, between November 2021 and February 2022. Results: Twenty-two responses from 20 different countries showed that organized breast cancer screening programs were present for 87% participants, and DCIS cases represented 13.7% of all breast cancers. Most participants used the grade classification (100%), the morphological classification (78%) and performed immunohistochemistry assays (73%). In case of conservative treatment, the mean re-excision rate was 10.3% and clear margins of mean 2.5 mm were considered healthy. Radical mastectomy rate was 35.5% with a breast reconstruction rate of 53%. Tumor bed boost indications were heterogeneous, and 73% of participants indicated hormone therapy for hormone-positive DCIS. Surgery and radiotherapy omission for some low-risk DCIS were considered by 73% of participants. Multigene assays were used by 43% of participants. Concerning future changes in DCIS management, participants mostly answered surgical de-escalation (48%), radiotherapy de-escalation (35) and/or active surveillance for some cases (22%). Conclusion: This survey provided an overview of the current practices of DCIS management worldwide. It showed that some areas are rather consensual: incidence increases over time, treatment in young women, pathological classifications, definition of healthy margins, the skin-sparing mastectomy and immediate breast reconstruction. However, some topics are still debated and result in heterogeneous practices, such as evolution in the age of diagnosis, the benefit of de-escalation in low-risk DCIS among elderly women, indications for hormone therapy, radiotherapy omission, or multigene assays. Further evidence is needed to reach consensus on these points, and innovative approaches are still under evaluation in clinical trials. The International Senologic Society, by its members, encourages precision medicine and personalized treatments for DCIS, to avoid overtreatment and overdiagnosis, and provide better healthcare to women with DCIS.


  • Breast Cancer Management During the COVID-19 Pandemic: The Senologic International Society Survey

    by Carole Mathelin, Shanti Ame, Stanley Anyanwu, Eli Avisar, Wahib Mohcen Boubnider, Katrin Breitling, Hannah Ayettey Anie, José Carlos Conceição, Veronique Dupont, Elisabeth Elder, et al.

    Objective: In early 2020, the spread of coronavirus disease-2019 (COVID-19) led the World Health Organization to declare this disease a pandemic. Initial epidemiological data showed that patients with cancer were at high risk of developing severe forms of COVID-19. National scientific societies published recommendations modifying the patients' breast cancer (BC) management to preserve, in theory, quality oncologic care, avoiding the increased risk of contamination. The Senology International Society (SIS) decided to take an inventory of the actions taken worldwide. This study investigates COVID-19-related changes concerning BC management and analyzes the will to maintain them after the pandemic, evaluating their oncological safety consequences. Materials and Methods: SIS network members participated in an online survey using a questionnaire (Microsoft (R) Forms) from June 15th to July 31st, 2020. Results: Forty-five responses from 24 countries showed that screening programs had been suspended (68%); magnetic resonance imagines were postponed (73%); telemedicine was preferred when possible (71%). Surgeries were postponed: reconstructive (77%), for benign diseases (84%), and in patients with significant comorbidities (66%). Chemotherapy and radiotherapy protocols had been adapted in 28% of patients in both. Exception for telemedicine (34%), these changes in practice should not be continued. Conclusion: The SIS survey showed significant changes in BC's diagnosis and treatment during the first wave of the COVID-19 pandemic, but most of these changes should not be maintained. Indeed, women have fewer severe forms of COVID-19 and are less likely to die than men. The risk of dying from COVID-19 is more related to the presence of comorbidities and age than to BC. Stopping screening and delaying treatment leads to more advanced stages of BC. Only women aged over 65 with BC under treatment and comorbidities require adaptation of their cancer management.


  • New Frontiers for Fairer Breast Cancer Care in a Globalized World

    by Didier Verhoeven, Claudia Allemani, Cary Kaufman, Sabine Siesling, Manuela Joore, Etienne Brain, Mauricio Magalhães Costa

    In early 2020, the book "Breast cancer: Global Quality Care" was published by Oxford University Press. In the year since then, publications, interviews (by ecancer), presentations, webinars, and virtual congress have been organized to disseminate further the main message of the project: "A call for Fairer Breast Cancer Care for all Women in a Globalized World." Special attention is paid to increasing the "value-based healthcare" putting the patient in the center of the care pathway and sharing information on high-quality integrated breast cancer care. Specific recommendations are made considering the local resource facilities. The multidisciplinary breast conference is considered "the jewel in the crown" of the integrated practice unit, connecting multiple specializations and functions concerned with patients with breast cancer. Management and coordination of medical expertise, facilities, and their interfaces are highly recommended. The participation of two world-leading cancer research programs, the CONCORD program and Breast Health Global Initiative, in this project has been particularly important. The project is continuously under review with feedback from the faculty. The future plan is to arrive at an openaccess publication that is freely available to all interested people. This project is designed to help ease the burden and suffering of women with breast cancer across the globe.


  • Methylation profiling in promoter sequences of ATM and CDKN2A (p14ARF/p16INK4a) genes in blood and cfDNA from women with impalpable breast lesions

    by Lucas Delmonico, Mauricio Augusto Silva Magalhães Costa, Romario José Gomes, Ana Beatriz Passos da Silva, Marcia V. Fournier, Luciano Rios Scherrer, Carolina Maria de Azevedo, Maria Helena Faria Ornellas, Gilda Alves, Pâmella de Oliveira Vieira

    The objective of the present study was to evaluate the epigenetic changes occurring in early stages of breast cancer. The present study investigated the methylation profile of the ATM, p14(ARF) and p16(INK4a) promoters in total blood and plasma cell-free DNA (cfDNA) from women with impalpable breast lesions compared with in total blood of a control cohort of women without breast lesions. The samples were evaluated using the methylation-specific PCR method. The Fisher's exact test was used to evaluate statistical significance between the methylation and clinical variables. A total of 111 women were evaluated, including 56 women with impalpable breast cancer (39/56 also had paired plasma cfDNA) and 55 women in the control cohort (55 blood DNA). For blood DNA from women with malignant impalpable breast lesions, p16(INK4a) exhibited the greatest percentage of methylation (48%), followed by ATM (37.5%) and p14(ARF) (27%) promoters, regardless of age variation. For plasma cfDNA, the methylation rates for ATM, p14(ARF) and p16(INK4a) were 26, 26 and 10%, respectively. The methylation rates for the blood DNA of controls were the lowest for ATM (9%), p14(ARF) (7%) and p16(INK4a) (7%). The women with impalpable breast lesions (benign and malignant lesions) exhibited the highest methylation rate, regardless of age, compared with the paired plasma cfDNA and controls. This epigenetic change was statistically significant for the promoters of ATM (P=0.009) and p16(INK4a) (P=0.001) (impalpable breast lesions vs. control). The present study demonstrated that epigenetic changes occurring in the ATM and CDKN2A genes detectable in liquid biopsy were associated with the development of impalpable breast lesions.


  • Abstract P1-01-06: Diagnostic accuracy of a novel palpation device to improve early detection of breast cancer in low-resource settings

    by Maurício M Costa, Anne F Rositch, Fernanda Pa Pereira, Hildoberto C de Oliveira, Carolina F de Oliveira, Nilson Gomes, Flávia Ppl Lopes

    Background and objectives: As the most commonly diagnosed cancer in women, breast cancer is projected to reach 1 million cases per year by 2020 in LMICs alone. Although incidence continues to increase in low- to middle-income countries, access to early detection in these high burden areas remain limited, in part due to lack of low-cost efficacious tools where mammography isn’t feasible. Therefore, the aim of this study is to evaluate the diagnostic accuracy of a lower cost, non-invasive, portable device called iBreastExam (iBE) in the detection of clinically relevant breast lesions. Methods: This study was a prospective non-randomized trial which enrolled women seeking routine screening or follow-up breast diagnostic evaluation from Nova Iguaçu and Rio de Janeiro, Brazil, respectively. Non-pregnant women aged 18 and older were eligible to enroll after providing informed consent. Each woman received an iBE palpation test and then mammography, ultrasound (US), or both, each by a different blinded clinician. For the sake of determining true lesion status, a positive mammogram was considered BIRADS 0, 3-6. A positive US was considered BIRADS 3-6. To assess accuracy of iBE to detect lesions, the sensitivity and specificity were calculated compared to mammography alone, ultrasound alone, or mammography plus ultrasound. For mammography plus US, the mammographic classification was considered the true status except for BIRADS 0, in which case the US classification was considered the truth. Each breast was considered an independent result for the sake of analysis. Results: The study enrolled and evaluated 226 women (449 breasts)with iBE, with a median age of 54 years old. Of the 434 breasts scanned by both iBE and mammography, 348 were normal by both and 17 lesions were detected by both. The sensitivity and specificity of iBE compared to mammography were 45.9% and 87.7%, respectively. Compared to the 324 US scans, where 258 normal by both and 20 lesions were detected by both, the sensitivity and specificity of iBE were 66.7% and 87.8%, respectively. Compared to mammography plus US, the sensitivity and specificity were 73.9% and 88.0%. Conclusions: Since iBE is being studied as a tool in resource-limited settings to facilitate early detection of suspicious breast lumps that warrant clinical follow-up, we chose other gold-standard diagnostic modalities and classifications, not detection of cancer, as our comparator. The relatively high specificity highlights the tools’ ability to reduce the pool of women warranting further evaluation but the sensitivity of iBE compared to mammography alone was relatively low. Notable, 15 of the 17 cases missed by iBE were classified as BIRADS 0. When these cases underwent US, the net sensitivity increased to 74%. These data highlight the potential for iBE to strengthen breast cancer early detection programs in LMIC’s and support the need for next generation sensors with improved sensitivity. Citation Format: Maurício M Costa, Anne F Rositch, Fernanda PA Pereira, Hildoberto C de Oliveira, Carolina F de Oliveira, Nilson Gomes, Flávia PPL Lopes. Diagnostic accuracy of a novel palpation device to improve early detection of breast cancer in low-resource settings [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P1-01-06.


  • Open Access

    A Novel Panel of 80 RNA Biomarkers with Differential Expression in Multiple Human Solid Tumors against Healthy Blood Samples

    by Lucas Delmonico, John C. Obenauer, Fatir Qureshi, Gilda Alves, Mauricio Augusto Silva Magalhães Costa, Katherine J. Martin, Marcia V. Fournier

    The aim of this study was to identify genes with higher expression in solid tumor cells by comparing human tumor biopsies with healthy blood samples using both in silico statistical analysis and experimental validations. This approach resulted in a novel panel of 80 RNA biomarkers with high discrimination power to detect circulating tumor cells in blood samples. To identify the 80 RNA biomarkers, Affymetrix HG-U133 plus 2.0 microarrays datasets were used to compare breast tumor tissue biopsies and breast cancer cell lines with blood samples from patients with conditions other than cancer. A total of 859 samples were analyzed at the discovery stage, consisting of 417 mammary tumors, 41 breast lines, and 401 control samples. To confirm this discovery, external datasets of eight types of tumors were used, and experimental validation studies (NanoString n-counter gene expression assay) were performed, totaling 5028 samples analyzed. In these analyses, the 80 biomarkers showed higher expression in all solid tumors analyzed relative to healthy blood samples. Experimental validation studies using NanoString assay confirmed the results were not dependent of the gene expression platform. A panel of 80 RNA biomarkers was described here, with the potential to detect solid tumor cells present in the blood of multiple tumor types.